Emapalumab, an anti-interferon-γ (IFN-γ) antibody, is approved for the treatment of primary HLH, but its use for the treatment of IEC-HS following CAR-T cell therapy, especially in adults, is limited and requires further investigation (3–6). Here, IFNG is linked to hemophagocytic syndrome.